REX Peptide ETF (PEPT)
| Assets | $3.23M |
| Expense Ratio | 0.65% |
| PE Ratio | n/a |
| Forward PE | n/a |
| Shares Out | 120,000 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 3,027 |
| Open | 26.98 |
| Previous Close | 26.97 |
| Day's Range | 26.72 - 27.09 |
| 52-Week Low | 25.06 |
| 52-Week High | 28.14 |
| Beta | n/a |
| Holdings | n/a |
| Inception Date | Oct 14, 2026 |
About PEPT
Fund Home PageThe REX Peptide ETF (PEPT) is an exchange-traded fund that is based on the VettaFi Peptide index. The fund seeks to track a market cap-weighted index of companies well-positioned to lead and support the full lifecycle of peptide-based products, from development and manufacturing through to commercial adoption. It specifically targets firms listed in developed markets exchanges or in a South Korean market exchange. PEPT was launched on Oct 14, 2026 and is issued by REX Shares.
News
What Is the Peptide Economy? Beyond the GLP-1 Boom
GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.
New Peptide ETF From REX Looks Beyond GLP-1 Drugs
A new peptide ETF launched today, holding the drugmakers behind GLP-1 weight-loss treatments along with the companies that make and deliver them. Key Takeaways: REX's new fund follows 36 peptide-linke...
REX Shares Launches REX Peptide ETF (PEPT)
MIAMI--(BUSINESS WIRE)--REX Shares (“REX”), a leading innovator in alternative ETFs, today announced the launch of the REX Peptide ETF (Ticker: PEPT), a thematic ETF built to own the peptide economy e...